Compare Moderna, Inc. (MRNA) vs NetApp Inc. (NTAP) Price & Performance

Moderna (MRNA) trades at $63.57, up 6.29% on the day, reflecting positive momentum following FDA approval of its mRNA flu vaccine, mFLUSIVA, for adults 50 and older. The stock exhibits a bullish technical outlook with moving averages supporting upward movement, though RSI levels suggest potential overbought conditions. Fundamentally, revenue has declined from pandemic peaks, with 2025 revenue at $1.92B and a net loss of -$2.82B, yet the company has beaten EPS estimates in recent quarters. Cash flow trends show improvement, with net cash flow turning positive in 2025 at $668M.

The outlook for MRNA hinges on pipeline execution beyond COVID-19, with recent vaccine approvals providing growth catalysts. Investment opportunities include diversification into flu, Ebola, and oncology therapies, but risks persist from high cash burn, competitive pressures, and reliance on successful clinical trials. Analyst sentiment is mixed with a consensus price target of $54.33, below the current price, indicating caution despite some bullish developments.

NetApp (NTAP) trades at $198.72, up 4.85% today, near its consensus price target high of $200. The stock shows strong technical momentum with bullish moving averages and recent earnings beats. Revenue grew to $6.57B in 2025 with an 18.43% net margin, while acquisitions like JetStream Software and DataPelago enhance its AI infrastructure capabilities. Cash flow turned positive at $840M in 2025 after two years of negative net flows.

Outlook is positive given earnings consistency and strategic AI investments, but high valuation ratios (P/E 31.26) and overbought RSI levels near 85 pose near-term risks. Analyst consensus leans Hold (50.7%), suggesting cautious optimism amid growth execution and competitive pressures in data storage.